Laura Ortega, NP
Family · Las Cruces, NMNPI 1245765494
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 196 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AstraZeneca at 24.2% of the total. 2025 is the largest year on record at $1,435, 8.2 times the $174 reported in 2021. Among family clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 196 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$914
- Novo Nordisk$711
- Lilly USA, LLC$571
- AbbVie$430
- Boehringer Ingelheim$243
- GSK$186
- plus $719 from 18 others
What the payments were for
- Food & beverage$3,757100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 41 | $914 |
| Novo Nordisk | 39 | $711 |
| Lilly USA, LLC | 36 | $571 |
| AbbVie | 25 | $430 |
| Boehringer Ingelheim | 9 | $243 |
| GSK | 10 | $186 |
| Nalu Medical, Inc. | 1 | $112 |
| Axsome Therapeutics, Inc. | 4 | $86 |
| Exact Sciences | 4 | $75 |
| Pfizer | 3 | $57 |
| Merck | 3 | $49 |
| Amgen | 3 | $48 |
| Radius Health, Inc. | 3 | $47 |
| Bayer | 2 | $38 |
| Xeris Pharmaceuticals, Inc. | 2 | $34 |
| Corium, LLC | 2 | $33 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $28 |
| Novartis | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Dexcom, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Mylan Specialty L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$228
- BREZTRI$131
- AIRSUPRA$131
- FARXIGA$131
- Nalu Neurostimulation System$112
How this compares
$3,773 in reported general payments places this provider in the 95th percentile of 1,080 family providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 32 | $43,461 |
| TrulicityDulaglutide | 29 | $42,309 |
| MounjaroTirzepatide | 28 | $39,834 |
| EliquisApixaban | 29 | $32,875 |
| JanuviaSitagliptin Phosphate | 23 | $31,063 |
| FarxigaDapagliflozin Propanediol | 30 | $30,946 |
| JardianceEmpagliflozin | 19 | $28,161 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $19,461 |
| RybelsusSemaglutide | 15 | $18,818 |
| XareltoRivaroxaban | 13 | $10,390 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $6,653 |
| Humalog Kwikpen U-200Insulin Lispro | 13 | $5,869 |
| Levothyroxine Sodium | 220 | $2,347 |
| Bupropion XlBupropion Hcl | 83 | $2,194 |
| Wixela InhubFluticasone Propion/Salmeterol | 19 | $1,951 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $571 | $82,14357 claims |
| Novo NordiskOzempic, Rybelsus | $711 | $62,27947 claims |
| PfizerEliquis, Paxlovid | $57 | $34,30440 claims |
| MerckJanuvia | $49 | $31,06323 claims |
| AstraZenecaFarxiga | $914 | $30,94630 claims |
| Boehringer IngelheimJardiance | $243 | $28,16119 claims |
| GSKTrelegy Ellipta | $186 | $19,46126 claims |
| AbbVieSynthroid | $430 | $1,88725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,080 family providers in New Mexico.
Other family in Las Cruces
- Jamie LujanLas Cruces$14K
- Joleen LeszczynskiLas Cruces$8K
- Deborah PachecoLas Cruces$6K
- Angelina CarverLas Cruces$5K
- Russell CoryellLas Cruces$5K
- Jessica AltamiranoLas Cruces$5K
- Rachel SaavedraLas Cruces$3K
- Thomas HaythLas Cruces$3K
- David SeiterFarmington$194K
- Carol HollandRoswell$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.